

Halo Biosciences Announces Selection as a Featured Company at the American Thoracic Society (ATS) 2024 Respiratory Innovation Summit

MAY 6, 2024 08:00 EST



PALO ALTO, California MAY 2, 2024 - Halo Biosciences, a clinical stage biopharmaceutical company advancing development of a treatment for pulmonary hypertension, announced today that it has been selected as a featured company to present at the American Thoracic Society (ATS) 2024 Respiratory Innovation Summit.

Concurrently, Halo Biosciences collaborators from Stanford University will present data from the proof-of-concept Phase 2a clinical trial of hymecromone in patients with pulmonary hypertension including Interstitial Lung Disease (The SATURN Study (NCT05128929)), which was accepted as a late breaking presentation at ATS.

During the Innovation Summit, Anissa Kalinowski, CEO of Halo Biosciences, will provide an overview of the company's recent progress and future plans. "It is an honor to be selected to provide an oral presentation at the 2024 Respiratory Innovation Summit. Our focus is on the proprietary formulation of hymecromone, an inhibitor of Hyaluronan synthesis (H1614), which would offer patients a new, first-in-class treatment that targets the extracellular matrix with disease modifying potential.", says Ms. Kalinowski. "While our science has relevance in a number of chronic diseases with significant unmet need, our lead program is focused on pulmonary hypertension and interstitial lung disease (PH-ILD, Group 3 PH). We look forward to sharing our plans with the extended ATS and RIS community."

Dr. Roham Zamanian, Professor at Stanford University and Director of the Vera Moulton Wall Center for Pulmonary Vascular Disease comments, “We are fortunate to have had the opportunity to collaborate with Halo Biosciences on the advance of a new mechanism for pulmonary hypertension. The need for new therapeutic options for our patients with Group 3 PH-ILD remains high, and we are enthusiastic about sharing the results of our Phase 2a study at ATS this year.”

ABOUT THE ATS RESPIRATORY INNOVATION SUMMIT

The ATS 2024 Respiratory Innovation Summit will unite the innovators, investors, clinicians, and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways. The summit will be held at the Manchester Grand Hyatt in San Diego, California on Friday, May 17 and Saturday, May 18.

Halo’s presentation was selected for presentation at Showcase Five: Fibrosis innovators, taking place on Saturday May 18, at 3pm.

More information on the American Thoracic Society’s 2024 Respiratory Innovation Summit can be found at <https://conference.thoracic.org/program/ris/>

ABOUT HALO BIOSCIENCES

Halo Biosciences is a clinical stage biopharmaceutical company redefining the treatment of inflammatory and fibrotic diseases. Halo Biosciences is developing a novel class of disease-modifying therapeutics that address underlying disease processes by editing the extracellular matrix (ECM). The

company's lead compound, H1614, specifically targets the dysregulation of hyaluronan (HA), a major component of the ECM, and a driver of edema, inflammation, and fibrosis. Following the successful completion of a Phase 1 study at Stanford University, H1614 is now in development for the treatment of Group 3 pulmonary hypertension (PH).

Contact Information

Anissa Kalinowski

Chief Executive Officer

Telephone for media and investors: +1 650 534 6111

Email for media and investors: anissa@halobiosciences.com

General inquiries: contactus@halobiosciences.com

Website: www.halobiosciences.com

Follow Halo Biosciences on LinkedIn [here](#)

Source: Halo Biosciences

###